SCHEMBL5404447

SCHEMBL5404447

CC(N)C(=O)Nc1cc(CO)cc(Nc2c3ccccc3nc3ccccc23)c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TOP2A P11388 10/20 0.66
TOP2B Q02880 9/20 0.66
L3MBTL1 Q9Y468 2/20 0.48
KDM4E B2RXH2 1/20 0.48
KDM1A O60341 1/20 0.48
MITF O75030 1/20 0.48
LMNA P02545 1/20 0.48
POLB P06746 1/20 0.48
MAPT P10636 1/20 0.48
RAD52 P43351 1/20 0.48
RECQL P46063 1/20 0.48
KMT2A Q03164 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
HDAC3 O15379 2/20 0.45
HDAC4 P56524 2/20 0.45
HDAC1 Q13547 2/20 0.45
HDAC7 Q8WUI4 2/20 0.45
HDAC2 Q92769 2/20 0.45
HDAC8 Q9BY41 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3989825 1.00 TOP2A (0.66) TOP2ATOP2BL3MBTL1KDM4EKDM1A
SCHEMBL5438138 0.93 TOP2A (0.58) TOP2ATOP2BKDM1A
SCHEMBL6545808 0.93 TOP2A (0.58) TOP2ATOP2BKDM1A
SCHEMBL3984667 0.91 TOP2A (0.64) TOP2ATOP2BL3MBTL1KDM4EKDM1A
SCHEMBL4257864 0.89 TOP2A (0.61) TOP2ATOP2BL3MBTL1KDM4EKDM1A
SCHEMBL3984729 0.89 TOP2A (0.60) TOP2ATOP2BL3MBTL1KDM4EKDM1A
SCHEMBL3990042 0.88 TOP2A (0.53) TOP2ATOP2BL3MBTL1KDM4EKDM1A
SCHEMBL5450024 0.88 TOP2A (0.53) TOP2ATOP2BL3MBTL1KDM4EKDM1A
SCHEMBL5428900 0.88 TOP2A (0.52) TOP2ATOP2BKDM1APOLBRAD52
SCHEMBL3981078 0.88 TOP2A (0.52) TOP2ATOP2BKDM1APOLBRAD52

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7230105-B2 9-aminoacridine derivatives and process for the preparation thereof SAMJIN PHARMACEUTICAL CO., LTD. (KR) 2007-06-12 US disclosed
US-7176320-B2 Benzimidazole derivative TEIJIN LIMITED (JP) 2007-02-13 US disclosed
US-20050222167-A1 9-aminoacridine derivatives and process for the preparation thereof SAMJIN PHARMACEUTICAL CO., LTD. (KR) 2005-10-06 US disclosed
EP-1487799-A4 9-AMINOACRIDINE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF SAMJIN PHARM CO LTD (KR) 2005-06-01 EP disclosed
EP-1487799-A1 9-AMINOACRIDINE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF Samjin Pharmaceutical Co., Ltd. (KR) 2004-12-22 EP disclosed
US-20040162311-A1 Benzimidazole derivative TEIJIN LIMITED 2004-08-19 US disclosed
US-20040010004-A1 Benzimidazole derivatives TEIJIN LIMITED (JP) 2004-01-15 US disclosed
WO-2003074490-A1 9-AMINOACRIDINE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF SAMJIN PHARMACEUTICAL CO., LTD. (KR) 2003-09-12 WO disclosed
EP-1249450-A1 BENZIMIDAZOLE DERIVATIVES TEIJIN LIMITED (JP) 2002-10-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040162311-A1 Benzimidazole derivative CMA1, CBR3, CBR1 TOP2A 3728/4885TOP2B 3525/4885L3MBTL1 2686/4885
US-20050222167-A1 9-aminoacridine derivatives and process for the preparation thereof PARP9, CASP9, AMPD2 TOP2A 131/4885TOP2B 209/4885L3MBTL1 1884/4885
US-20040010004-A1 Benzimidazole derivatives CMA1, CBR3, CBR1 TOP2A 3744/4885TOP2B 3550/4885L3MBTL1 2655/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.